Mergers and acquisitions (M&As) in biopharma have rebounded with a $76.9 billion increase in total deal value seen from 2022 to 2023, according to GlobalData. 14 May 2024
With the annual meeting of the American Society of Clinical Oncology (ASCO) now only weeks away, more drugmakers and research groups are lifting the lid on data 14 May 2024
Diversified German drugmaker Bayer has reported group sales of 13.8 billion euros ($14.9 billion) for the first quarter, a fall of around 0.6%, meeting expectat 14 May 2024
Oncology companies including New York-based giant Pfizer (NYSE: PFE) and Japan’s Astellas Pharma (TSE: 4503) have outlined details of data they intend to presen 13 May 2024
Immuno-oncology company iTeos Therapeutics has lofty ambitions, claiming to be pioneering the discovery and development of a new generation of highly differenti 13 May 2024
Despite a lower dose, data from the Phase II stage of the TAMARACK study have raised concerns over the safety profile of MacroGenics’ antibody-drug conjugate (A 13 May 2024
Companies including Gilead Sciences unit Kite, as well as Boston-based Treos Bio, have outlined data they intend to present at the upcoming annual meeting of th 9 May 2024
Accord BioPharma—the US specialty division of Intas Pharmaceuticals— has won US Food and Drug Administration (FDA) approval for Hercessi (trastuzumab-strf), a b 9 May 2024
Leading biotech incubator Flagship Pioneering has announced its latest investment, with the launch of a viral proteome start-up, Prologue Medicines. 8 May 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.